Ad is loading...
ARWR
Price
$18.71
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
4 days until earnings call
EDIT
Price
$2.41
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
96 days until earnings call
Ad is loading...

ARWR vs EDIT

Header iconARWR vs EDIT Comparison
Open Charts ARWR vs EDITBanner chart's image
Arrowhead Pharmaceuticals
Price$18.71
Change-$0.00 (-0.00%)
Volume$792.15K
CapitalizationN/A
Editas Medicine
Price$2.41
Change-$0.00 (-0.00%)
Volume$2.82M
CapitalizationN/A
ARWR vs EDIT Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARWR vs. EDIT commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Sell and EDIT is a Buy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (ARWR: $18.28 vs. EDIT: $2.37)
Brand notoriety: ARWR: Notable vs. EDIT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 69% vs. EDIT: 130%
Market capitalization -- ARWR: $2.27B vs. EDIT: $198.94M
ARWR [@Biotechnology] is valued at $2.27B. EDIT’s [@Biotechnology] market capitalization is $198.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and EDIT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 6 bearish.
  • EDIT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -14.62% price change this week, while EDIT (@Biotechnology) price change was -14.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

ARWR is expected to report earnings on Feb 05, 2025.

EDIT is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.27B) has a higher market cap than EDIT($199M). ARWR YTD gains are higher at: -40.261 vs. EDIT (-76.604). EDIT has higher annual earnings (EBITDA): -222.63M vs. ARWR (-508.26M). ARWR has more cash in the bank: 434M vs. EDIT (265M). EDIT has less debt than ARWR: EDIT (38.5M) vs ARWR (118M). EDIT has higher revenues than ARWR: EDIT (61.8M) vs ARWR (19.6M).
ARWREDITARWR / EDIT
Capitalization2.27B199M1,142%
EBITDA-508.26M-222.63M228%
Gain YTD-40.261-76.60453%
P/E RatioN/AN/A-
Revenue19.6M61.8M32%
Total Cash434M265M164%
Total Debt118M38.5M306%
FUNDAMENTALS RATINGS
ARWR vs EDIT: Fundamental Ratings
ARWR
EDIT
OUTLOOK RATING
1..100
1852
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8395
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
9575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (21) in the Biotechnology industry is significantly better than the same rating for ARWR (95). This means that EDIT’s stock grew significantly faster than ARWR’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that EDIT’s stock grew similarly to ARWR’s over the last 12 months.

EDIT's SMR Rating (98) in the Biotechnology industry is in the same range as ARWR (98). This means that EDIT’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (83) in the Biotechnology industry is in the same range as EDIT (95). This means that ARWR’s stock grew similarly to EDIT’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that ARWR’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWREDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 16 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIAGX14.630.28
+1.95%
Timothy Plan Small/Mid Cap Growth Cl I
JVTAX87.991.29
+1.49%
Janus Henderson Venture A
RSGRX32.770.23
+0.71%
Victory RS Growth A
WFSPX698.023.81
+0.55%
iShares S&P 500 Index K
EIHSX14.560.07
+0.48%
Eaton Vance Worldwide Health Sci I

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-2.30%
NTLA - ARWR
50%
Loosely correlated
+5.18%
CRNX - ARWR
48%
Loosely correlated
+1.71%
EDIT - ARWR
47%
Loosely correlated
-1.66%
BEAM - ARWR
46%
Loosely correlated
-3.72%
ALNY - ARWR
46%
Loosely correlated
-0.80%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-1.66%
NTLA - EDIT
64%
Loosely correlated
+5.18%
CRSP - EDIT
64%
Loosely correlated
-2.05%
BEAM - EDIT
64%
Loosely correlated
-3.72%
VERV - EDIT
54%
Loosely correlated
+1.10%
AXON - EDIT
52%
Loosely correlated
+3.52%
More